Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 31

1.

Integrins in cancer: biological implications and therapeutic opportunities.

Desgrosellier JS, Cheresh DA.

Nat Rev Cancer. 2010 Jan;10(1):9-22. doi: 10.1038/nrc2748. Review.

2.

Tissue-penetrating delivery of compounds and nanoparticles into tumors.

Sugahara KN, Teesalu T, Karmali PP, Kotamraju VR, Agemy L, Girard OM, Hanahan D, Mattrey RF, Ruoslahti E.

Cancer Cell. 2009 Dec 8;16(6):510-20. doi: 10.1016/j.ccr.2009.10.013.

3.

C-end rule peptides mediate neuropilin-1-dependent cell, vascular, and tissue penetration.

Teesalu T, Sugahara KN, Kotamraju VR, Ruoslahti E.

Proc Natl Acad Sci U S A. 2009 Sep 22;106(38):16157-62. doi: 10.1073/pnas.0908201106. Epub 2009 Sep 2.

4.

Systematic surface engineering of magnetic nanoworms for in vivo tumor targeting.

Park JH, von Maltzahn G, Zhang L, Derfus AM, Simberg D, Harris TJ, Ruoslahti E, Bhatia SN, Sailor MJ.

Small. 2009 Mar;5(6):694-700. doi: 10.1002/smll.200801789.

5.

Is anticancer drug development heading in the right direction?

Hambley TW, Hait WN.

Cancer Res. 2009 Feb 15;69(4):1259-62. doi: 10.1158/0008-5472.CAN-08-3786. Epub 2009 Feb 10.

6.

Enhanced antitumor efficacy of clinical-grade vasculature-targeted liposomal doxorubicin.

Pastorino F, Di Paolo D, Piccardi F, Nico B, Ribatti D, Daga A, Baio G, Neumaier CE, Brignole C, Loi M, Marimpietri D, Pagnan G, Cilli M, Lepekhin EA, Garde SV, Longhi R, Corti A, Allen TM, Wu JJ, Ponzoni M.

Clin Cancer Res. 2008 Nov 15;14(22):7320-9. doi: 10.1158/1078-0432.CCR-08-0804.

7.

Targeting of albumin-embedded paclitaxel nanoparticles to tumors.

Karmali PP, Kotamraju VR, Kastantin M, Black M, Missirlis D, Tirrell M, Ruoslahti E.

Nanomedicine. 2009 Mar;5(1):73-82. doi: 10.1016/j.nano.2008.07.007. Epub 2008 Oct 1.

8.

The role of doxorubicin and epirubicin in the treatment of patients with metastatic hormone-refractory prostate cancer.

Petrioli R, Fiaschi AI, Francini E, Pascucci A, Francini G.

Cancer Treat Rev. 2008 Dec;34(8):710-8. doi: 10.1016/j.ctrv.2008.05.004. Epub 2008 Jul 11. Review.

PMID:
18620815
9.

Nanoparticle-mediated drug delivery to tumor vasculature suppresses metastasis.

Murphy EA, Majeti BK, Barnes LA, Makale M, Weis SM, Lutu-Fuga K, Wrasidlo W, Cheresh DA.

Proc Natl Acad Sci U S A. 2008 Jul 8;105(27):9343-8. doi: 10.1073/pnas.0803728105. Epub 2008 Jul 7.

10.

Neuropilins: structure, function and role in disease.

Pellet-Many C, Frankel P, Jia H, Zachary I.

Biochem J. 2008 Apr 15;411(2):211-26. doi: 10.1042/BJ20071639. Review.

PMID:
18363553
11.

Semaphorin 3A suppresses VEGF-mediated angiogenesis yet acts as a vascular permeability factor.

Acevedo LM, Barillas S, Weis SM, Göthert JR, Cheresh DA.

Blood. 2008 Mar 1;111(5):2674-80. doi: 10.1182/blood-2007-08-110205. Epub 2008 Jan 7.

12.

Drug penetration in solid tumours.

Minchinton AI, Tannock IF.

Nat Rev Cancer. 2006 Aug;6(8):583-92. Review.

PMID:
16862189
13.

Characterization of a bicyclic peptide neuropilin-1 (NP-1) antagonist (EG3287) reveals importance of vascular endothelial growth factor exon 8 for NP-1 binding and role of NP-1 in KDR signaling.

Jia H, Bagherzadeh A, Hartzoulakis B, Jarvis A, Löhr M, Shaikh S, Aqil R, Cheng L, Tickner M, Esposito D, Harris R, Driscoll PC, Selwood DL, Zachary IC.

J Biol Chem. 2006 May 12;281(19):13493-502. Epub 2006 Mar 2.

14.

Applications of major histocompatibility complex class I molecules expressed as single chains.

Primeau T, Myers NB, Yu YY, Lybarger L, Wang X, Truscott SM, Hansen TH, Connolly JM.

Immunol Res. 2005;32(1-3):109-21. Review.

PMID:
16106063
15.

Modulation of brain tumor capillaries for enhanced drug delivery selectively to brain tumor.

Black KL, Ningaraj NS.

Cancer Control. 2004 May-Jun;11(3):165-73. Review.

16.

Stage-specific vascular markers revealed by phage display in a mouse model of pancreatic islet tumorigenesis.

Joyce JA, Laakkonen P, Bernasconi M, Bergers G, Ruoslahti E, Hanahan D.

Cancer Cell. 2003 Nov;4(5):393-403.

17.

Progressive vascular changes in a transgenic mouse model of squamous cell carcinoma.

Hoffman JA, Giraudo E, Singh M, Zhang L, Inoue M, Porkka K, Hanahan D, Ruoslahti E.

Cancer Cell. 2003 Nov;4(5):383-91.

18.

Vascular reactions to histamine, histamine-liberator and leukotaxine in the skin of guinea-pigs.

MILES AA, MILES EM.

J Physiol. 1952 Oct;118(2):228-57. No abstract available.

19.

Vascular permeability enhancement in solid tumor: various factors, mechanisms involved and its implications.

Maeda H, Fang J, Inutsuka T, Kitamoto Y.

Int Immunopharmacol. 2003 Mar;3(3):319-28. Review.

PMID:
12639809
20.

Specialization of tumour vasculature.

Ruoslahti E.

Nat Rev Cancer. 2002 Feb;2(2):83-90. Review.

PMID:
12635171

Supplemental Content

Support Center